Rodman W. Moorhead, III Joins Cellphire, Inc. Board of Directors

Screen Shot 2018-03-24 at 8.16.43 AM Screen Shot 2018-03-24 at 8.16.37 AM

Rodman W. Moorhead, III Joins Cellphire, Inc. Board of Directors

NOVEMBER 1, 2016 

Rockville, MD, November 1, 2016 – Cellphire, Inc. announced today the appointment of Mr. Rodman W. Moorehead, III to its Board of Directors.  Mr. Moorhead retired from Warburg Pincus, a global private equity firm, after a career spanning 37 years. His last position at Warburg Pincus was as Senior Advisor and Managing Director of its Life Sciences practice. He is Chairman of the Board of The Taft School, a member of the Harvard Medical School Board of Fellows, Chairman of Stroud Water Research Center, trustee of the Brandywine Conservancy and trustee of the Jackson Hole Land Trust.  Mr. Moorhead holds an AB in Economics from Harvard College and an MBA from Harvard Business School.

“Rod Moorhead is a tremendous addition to Cellphire’s Board,” said CEO Stephen Willard, “He brings many years of experience at the highest levels of healthcare finance, and we look forward to working with him in the years ahead.”

# # #


About Cellphire Therapeutics, Inc. 

Cellphire Therapeutics, Inc. ( is working to solve the ubiquitous shortage of platelets for treatment of traumatic bleeding and other blood-related problems.  Platelets are critical to the body’s vascular system, responsible for the body’s ability to stop bleeding.  Unlike other blood products that can be frozen and stockpiled for use when needed, platelets must be stored at room temperature, and they spoil after just five days. Cellphire’s lead product, Thrombosomes®, a human platelet-derived hemostatic agent, uses a proprietary technology to freeze-dry platelets into a powder that can be stored for years, then reconstituted and brought back to life with sterilized water. Cellphire’s platform technology has tremendous potential across a wide range of medical applications from trauma to wound care, anti-coagulant reversal, imaging, targeted drug delivery and regenerative medicine.  

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipated”, “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Cellphire’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, increased regulatory requirements, Cellphire’s reliance on third parties over which it may not always have full control, and others. Any forward-looking statements speak only as of the date of this press release and are based on information available to Cellphire as of the date of this release, and Cellphire assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Thomas Dann
(240) 268-2489


Source:  Cellphire Therapeutics, Inc.